Waskyra™ Receives Positive Opinion from CHMP for WAS Treatment
Fondazione Telethon has received an enthusiastic endorsement from the Committee for Medicinal Products for Human Use (CHMP) within the European Medicines Agency (EMA). This endorsement marks a pivotal moment, paving the way for marketing authorization of Waskyra™, a groundbreaking gene therapy designed to treat Wiskott-Aldrich Syndrome (WAS). This rare and severe immunodeficiency condition presents unique challenges, and this therapy offers renewed hope for affected individuals.
Innovative Journey from Research to Approval
For Fondazione Telethon, this achievement is particularly noteworthy as it is the first non-profit organization to navigate successfully the complex journey from initial research to obtaining regulatory approval. By collaborating with industry partners, it has transitioned innovations in gene therapy into practical treatments available for patients in need.
Developed over many years at the renowned San Raffaele Telethon Institute for Gene Therapy in Milan, Waskyra™ stands as a testament to rigorous scientific research. It embodies the persistent dedication of researchers striving to enhance the quality of life for those affected by WAS.
Thoughts from the Leadership
"This significant milestone showcases the influence of academic research, particularly when it is executed with a patient-first attitude and adheres to the highest standards of industrial practices," stated Ilaria Villa, General Director of Fondazione Telethon. The commitment to ensuring that laboratory innovations reach those in need underscores the dedication to bridging the gap between science and patient care.
Dr. Alessandro Aiuti, Deputy Director of Clinical Research at SR-Tiget, echoed this sentiment, emphasizing that making these therapies accessible is crucial for offering families real treatment opportunities. His insights reflect a deep understanding of the intersection between science and its tangible impacts on lives.
Clinical Availability and Future Review
Patients can expect access to the therapy at IRCCS Ospedale San Raffaele, a facility recognized for its expertise in gene therapies, which has played a vital role in the trial phase of this promising treatment. Ongoing collaboration with regulatory authorities implies a continued commitment to making cutting-edge therapies available to all eligible individuals.
While the Biologics License Application for the same therapy is currently under review by the U.S. Food and Drug Administration (FDA), Fondazione Telethon remains committed to supporting the regulatory process, ensuring the therapeutic advancements translate into real-world benefits for those impacted by this condition.
Understanding Wiskott-Aldrich Syndrome (WAS)
Wiskott-Aldrich syndrome, a genetic disorder characterized by immunodeficiency and low platelet counts, emerges from mutations in the WAS gene. Early childhood symptoms frequently include recurrent infections and bleeding episodes, alongside eczema and heightened risks for autoimmune disorders and lymphomas.
This disorder predominantly affects males, with an incidence rate estimated at 1 in 250,000 live male births. Current strategies for managing the condition focus on supportive therapies aimed at alleviating clinical issues. Unfortunately, the only curative option available is hematopoietic stem cell transplantation, a process that may not be accessible for all patients due to donor availability and potential complications.
An Overview of Waskyra™
Waskyra™ (etuvetidigene autotemcel) is administered as a single dose of autologous CD34+ hematopoietic stem and progenitor cells. These cells are engineered using a lentiviral vector that carries the functional WAS gene, providing a remedy for patients.
Prior to reinfusion, patients undergo chemotherapy to optimize their bone marrow for receiving the corrected stem cells. Clinical evidence supports that Waskyra™ significantly diminishes the occurrence of severe bleeding and infections, thus offering renewed hope for those with WAS, particularly when familial donor options are impractical.
About Fondazione Telethon
Fondazione Telethon is a distinguished Italian non-profit organization dedicated to advancing research in rare genetic disorders. With a legacy spanning over 35 years, it strives to propel impactful scientific studies aimed at discovering innovative therapies and enhancing the lives of individuals living with such conditions.
Frequently Asked Questions
What is Waskyra™?
Waskyra™ is an ex vivo gene therapy developed to treat Wiskott-Aldrich syndrome, offering a potential solution for affected patients.
What is the importance of the CHMP positive opinion?
The CHMP positive opinion is crucial as it recommends authorization for Waskyra™ in the European Union, enabling access to this innovative therapy.
Who can benefit from Waskyra™?
Patients diagnosed with Wiskott-Aldrich syndrome, particularly those lacking suitable donors for stem cell transplantation, can benefit from Waskyra™.
How does Waskyra™ work?
Waskyra™ involves correcting patient’s stem cells with a lentiviral vector carrying the WAS gene, followed by reinfusion after chemotherapy preparation.
What role does Fondazione Telethon play?
Fondazione Telethon leads efforts in gene therapy research and development, facilitating pathways for innovative treatments in rare diseases.
